UPDATE 2-Canada's Angiotech to file for bankruptcy
* Says recapitalization deal to cut debt by $250 mln
* Deal supported by majority of subordinated noteholders
* Lines up $25 mln DIP loan
* Existing shareholders to be wiped out (Adds details of settlement with former stockholders of Quill Medical)
Jan 28 (Reuters) - Angiotech Pharmaceuticals Inc ANP.TO said it will file for bankruptcy protection under Canada's Companies' Creditors Arrangement Act to cut $250 million of its debt.
All of the company's existing shareholders will be wiped out without any compensation under a proposed recapitalization deal. The transaction is supported by noteholders representing more than 84 percent of the outstanding subordinated notes.
The Vancouver-based company, a specialty pharmaceutical and medical device maker, has been hit hard by declining sales of its Taxus coronary stent systems.
Angiotech has also lined up a $25 million debtor-in-possession loan from Wells Fargo Capital Finance LLC to continue operations while under creditor protection.
Under the proposed plan, noteholders will exchange their subordinated notes for a share in 96 percent of the reorganized company's common stock, Angiotech said in a statement.
The company has also agreed to pay $6 million to former shareholders of Quill Medical Inc to settle a lawsuit filed last October.
The lawsuit alleged that Angiotech, which acquired Quill Medical in 2006, misrepresented or made omissions during negotiations for the merger. (Reporting by Santosh Nadgir in Bangalore; Editing by Sriraj Kalluvila and Gopakumar Warrier)
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video